Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Bioartificial liver"

Keywords

Publication year

"Bioartificial liver"

Review

Background
Fulminant hepatic failure is a devastating process associated with high mortality, but no sequele after recovep. At the moment, there are no specific therapeutic modalities except for the orthotopic liver transplantation(OLT) which is limited to a small number of patients due to a lack of donor organ. Recently, several nonsurgical managements have been investigated to overcome the donor shortage and to bridge patients to OLT. These include artificial hepatic support systems, hepatocyte transplantation and extracorporeal liver support. Xenotransplantation is also being investigated to circumbent the donor shortage. Hepatocyte transplantation:The application of liver cell transplantation has been envisioned for temporary metabolic support during liver failure, provision of specific liver functions in inherited metabolic diseases of the liver and as a vehicle for ex vivo gene therapy. Potential advantages over OLT are that the procedure is simple, hepatoyctes can be cryopreserved for immediate use in need, the cost is less expensive and abrogation of allograft rejection may be easier by the modification of antigenicity during culture. Moreover, donor shortage can be overcome by the use of fetal hepatocytes, conditionally immortalized hepatocytes and possibly liver progenitor cells. However, the optimum route and the method are still being investigated. Recently, biodegradable matrix or cotransplantation with non-parencymal liver cells is used to improve and prolong the survival of transplanted hepatocytes in the peritoneum, and injection of donor type splenocytes into the thymus along with ablation of the peripheral lymphocytes with antilymphocyte globulin is adopted to tolerize the recipient to allogeneic hepatocytes. BioartiTicial liver:Presently, several bioartificial liver systems use mammalian hepatocytes held within cartridges, mostly hollow- fiber bioreactor perfused by plasma or whole blood. Plasma is separated from patient blood using Background:Fulminant hepatic failure is a devastating process associated with high mortality, but no sequele after recovep. At the moment, there are no specific therapeutic modalities except for the orthotopic liver transplantation(OLT) which is limited to a small number of patients due to a lack of donor organ. Recently, several nonsurgical managements have been investigated to overcome the donor shortage and to bridge patients to OLT. These include artificial hepatic support systems, hepatocyte transplantation and extracorporeal liver support. Xenotransplantation is also being investigated to circumbent the donor shortage. Hepatocyte transplantation:The application of liver cell transplantation has been envisioned for temporary metabolic support during liver failure, provision of specific liver functions in inherited metabolic diseases of the liver and as a vehicle for ex vivo gene therapy. Potential advantages over OLT are that the procedure is simple, hepatoyctes can be cryopreserved for immediate use in need, the cost is less expensive and abrogation of allograft rejection may be easier by the modification of antigenicity during culture. Moreover, donor shortage can be overcome by the use of fetal hepatocytes, conditionally immortalized hepatocytes and possibly liver progenitor cells. However, the optimum route and the method are still being investigated. Recently, biodegradable matrix or cotransplantation with non-parencymal liver cells is used to improve and prolong the survival of transplanted hepatocytes in the peritoneum, and injection of donor type splenocytes into the thymus along with ablation of the peripheral lymphocytes with antilymphocyte globulin is adopted to tolerize the recipient to allogeneic hepatocytes. BioartiTicial liver:Presently, several bioartificial liver systems use mammalian hepatocytes held within cartridges, mostly hollow- fiber bioreactor perfused by plasma or whole blood. Plasma is separated from patient blood using
  • 3,931 View
  • 16 Download

Original Article

Isolation and Culture of Pig Hepatocyte in Large Scale for the Application of Bioartificial Liver System
Yu Jeong Chung2, Hyuk-Joon Lee1, Young Taeg Koh3, Sang Beom Kim1 , Seong Hoon Kim1, Seokho Choi1, Nam-Joon Yi11, Seong-Hwan Chang1, Eun Lan Yang2, Kyung-Suk Suh1, Yoon Shin Lee4 , and Kuhn Uk Lee1,2
Korean J Hepatol 2002;8(3):249-255.
Background/Aims
Acute hepatic failure is a serious problem. Its mortality reaches up to 80%. Only liver transplantation has been accepted as a definite treatment for patients with hepatic failure but shortage of donor organs is the main obstacle of this approach. A possible solution to this problem is a bioartificial liver system, perfusion of patients blood to isolated hepatocyte. In this study, we performed the isolation and culture of pig hepatocyte in large scale for the application of bioartificial liver system. Methods: Hepatocyte isolation was performed by two-step collagenase method via portal vein perfusion in 10kg female pigs. After that, we compared the functional differences of the spheroid culture to the monolayer culture of hepatocyte. The viability and the function of hepatocyte were assessed using trypan-blue exclusion test and the measurement of the rate of ureagenesis and ammonia removal. Results: The average viability and yield of hepatocyte were 86.8±8.0 % and 7.8±5.4×109, respectively. The spheroid culture was superior to the monolayer culture in functional aspect of hepatocyte, and their differences, especially for ammonia removal, were more apparent in parallel with culture time. Conclusions: For hepatocyte isolation, we obtained sufficient viability and yield of hepatocyte for clinical usage of bioartificial liver system. The function of hepatocyte seems to be better in the spheroid culture than in the monolayer culture. Further studies are needed for application of bioartificial liver system in clinical setting. (Korean J Hepatol 2002;8:249-255)
  • 3,841 View
  • 24 Download